{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:52:30Z","timestamp":1791899550965,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N.A."],"award-info":[{"award-number":["N.A."]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10637-019-00754-y","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T08:03:23Z","timestamp":1552896203000},"page":"120-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody\u2013drug conjugate, in patients with breast cancer and other advanced solid tumors"],"prefix":"10.1007","volume":"38","author":[{"given":"Lee S.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Baffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Hsin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Pirie-Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ctrv.2017.08.011","volume":"60","author":"S Inder","year":"2017","unstructured":"Inder S, O'Rourke S, McDermott N, Manecksha R, Finn S, Lynch T, Marignol L (2017) The Notch-3 receptor: a molecular switch to tumorigenesis? Cancer Treat Rev 60:69\u201376","journal-title":"Cancer Treat Rev"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1038\/onc.2008.230","volume":"27","author":"D Bellavia","year":"2008","unstructured":"Bellavia D, Checquolo S, Campese AF (2008) Notch3: from subtle structural differences to functional diversity. Oncogene 27:5092\u20135098","journal-title":"Oncogene"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2011.11.028","volume":"317","author":"J Izrailit","year":"2012","unstructured":"Izrailit J, Reedijk M (2012) Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications. Cancer Lett 317:115\u2013126","journal-title":"Cancer Lett"},{"key":"754_CR4","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1016\/j.biocel.2009.08.019","volume":"41","author":"L Jia","year":"2009","unstructured":"Jia L, Yu G, Zhang Y, Wang MM (2009) Lysosome dependent degradation of Notch3. Int J Biochem Cell Biol 41:2594\u20132598","journal-title":"Int J Biochem Cell Biol"},{"key":"754_CR5","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2353\/ajpath.2006.050416","volume":"168","author":"C Hu","year":"2006","unstructured":"Hu C, Dievart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P (2006) Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol 168:973\u2013990","journal-title":"Am J Pathol"},{"key":"754_CR6","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1158\/0008-5472.CAN-13-0409","volume":"73","author":"H Ling","year":"2013","unstructured":"Ling H, Sylvestre JR, Jolicoeur P (2013) Cyclin D1-dependent induction of luminal inflammatory breast tumors by activated notch3. Cancer Res 73:5963\u20135973","journal-title":"Cancer Res"},{"key":"754_CR7","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-11-2258","volume":"18","author":"AM Egloff","year":"2012","unstructured":"Egloff AM, Grandis JR (2012) Molecular pathways: context-dependent approaches to notch targeting as cancer therapy. Clin Cancer Res 18:5188\u20135195","journal-title":"Clin Cancer Res"},{"key":"754_CR8","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1158\/0008-5472.CAN-07-1597","volume":"68","author":"N Yamaguchi","year":"2008","unstructured":"Yamaguchi N, Oyama T, Ito E, Satoh H, Azuma S, Hayashi M, Shimizu K, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Ohwada S, Tatsuta K, Inoue J, Semba K, Watanabe S (2008) NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res 68:1881\u20131888","journal-title":"Cancer Res"},{"key":"754_CR9","first-page":"35","volume":"23","author":"H Hirose","year":"2010","unstructured":"Hirose H, Ishii H, Mimori K, Ohta D, Ohkuma M, Tsujii H, Saito T, Sekimoto M, Doki Y, Mori M (2010) Notch pathway as candidate therapeutic target in Her2\/Neu\/ErbB2 receptor-negative breast tumors. Oncol Rep 23:35\u201343","journal-title":"Oncol Rep"},{"key":"754_CR10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2353\/ajpath.2010.090476","volume":"177","author":"Z Zhang","year":"2010","unstructured":"Zhang Z, Wang H, Ikeda S, Fahey F, Bielenberg D, Smits P, Hauschka PV (2010) Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis. Am J Pathol 177:1459\u20131469","journal-title":"Am J Pathol"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1158\/0008-5472.CAN-04-3132","volume":"65","author":"N Haruki","year":"2005","unstructured":"Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A, Carbone DP, Dang TP (2005) Dominant negative Notch3 receptor inhibits mitogen activated protein kinase pathway and the growth of human lung cancers. Cancer Res 65:3555\u20133561","journal-title":"Cancer Res"},{"key":"754_CR12","doi-asserted-by":"publisher","first-page":"6312","DOI":"10.1158\/0008-5472.CAN-05-3610","volume":"66","author":"JT Park","year":"2006","unstructured":"Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih IM, Wang TL (2006) Notch3 gene amplification in ovarian cancer. Cancer Res 66:6312\u20136318","journal-title":"Cancer Res"},{"key":"754_CR13","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/j.1349-7006.2010.01641.x","volume":"101","author":"SG Jung","year":"2010","unstructured":"Jung SG, Kwon YD, Song JA, Back MJ, Lee SY, Lee C, Hwang YY, An HJ (2010) Prognostic significance of notch 3 gene expression in ovarian serous carcinoma. Cancer Sci 101:1977\u20131983","journal-title":"Cancer Sci"},{"key":"754_CR14","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1158\/0008-5472.CAN-11-2181","volume":"72","author":"X Chen","year":"2012","unstructured":"Chen X, Thiaville MM, Chen L, Stoeck A, Xuan J, Gao M, Shih IM, Wang TL (2012) Defining NOTCH3 target genes in ovarian cancer. Cancer Res 72:2294\u20132303","journal-title":"Cancer Res"},{"key":"754_CR15","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/carcin\/bgt127","volume":"34","author":"KM Capaccione","year":"2013","unstructured":"Capaccione KM, Pine SR (2013) The notch signaling pathway as a mediator of tumor survival. Carcinogenesis 34:1420\u20131430","journal-title":"Carcinogenesis"},{"key":"754_CR16","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1517\/13543784.2011.582866","volume":"20","author":"P Sapra","year":"2011","unstructured":"Sapra P, Hooper AT, O'Donnell CJ, Gerber HP (2011) Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 20:1131\u20131149","journal-title":"Expert Opin Investig Drugs"},{"key":"754_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10637-016-0419-7","volume":"35","author":"G Shapiro","year":"2017","unstructured":"Shapiro G, Vaishampayan U, LoRusso P, Barton J, Hua S, Reich SD, Shazer R, Taylor CT, Xuan D, Borghaei H (2017) First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Investig New Drugs 35:315\u2013323","journal-title":"Investig New Drugs"},{"issue":"15 Suppl","key":"754_CR18","doi-asserted-by":"crossref","first-page":"Abstract 1697","DOI":"10.1158\/1538-7445.AM2015-1697","volume":"75","author":"KG Geles","year":"2015","unstructured":"Geles KG, Gao Y, Sridharan L, Giannakou A, Yamin T-T, Golas J, Lucas J, Charati M, Li X, Guffroy M, Nichols T, Wang K, Follettie M, Maderna A, Tchistiakova L, Gerber H-P, Sapra P (2015) Therapeutic targeting the NOTCH3 receptor with antibody drug conjugates. Cancer Res 75(15 Suppl):Abstract 1697","journal-title":"Cancer Res"},{"key":"754_CR19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/sim.4780141102","volume":"4","author":"SN Goodman","year":"1995","unstructured":"Goodman SN, Zahurak ML, Piantadosi S (1995) Some practical improvements in the continual reassessment method for phase I studies. Stat Med 4:1149\u20131161","journal-title":"Stat Med"},{"key":"754_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2307\/2531628","volume":"46","author":"J O\u2019Quigley","year":"1990","unstructured":"O\u2019Quigley J, Pepe M, Fisher L (1990) Continual reassessment method. A practical design for phase 1 clinical trials in cancer. Biometrics 46:33\u201348","journal-title":"Biometrics"},{"key":"754_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1158\/1078-0432.CCR-14-0809","volume":"21","author":"RA Previs","year":"2015","unstructured":"Previs RA, Coleman RL, Harris AL, Sood AK (2015) Molecular pathways: translational and therapeutic implications of the notch signaling pathway in cancer. Clin Cancer Res 21:955\u2013961","journal-title":"Clin Cancer Res"},{"key":"754_CR22","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/0008-5472.CAN-16-1022","volume":"77","author":"L Choy","year":"2017","unstructured":"Choy L, Hagenbeek TJ, Solon M, French D, Finkle D, Shelton A, Venook R, Brauer MJ, Siebel CW (2017) Constitutive NOTCH3 signaling promotes the growth of basal breast cancers. Cancer Res 77:1439\u20131452","journal-title":"Cancer Res"},{"key":"754_CR23","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1158\/1078-0432.CCR-14-2808","volume":"21","author":"WC Yen","year":"2015","unstructured":"Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, Tang T, Wallace B, Wang M, Zhang C, Kapoun AM, Lewicki J, Gurney A, Hoey T (2015) Targeting notch signaling with a Notch2\/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res 21:2084\u20132095","journal-title":"Clin Cancer Res"},{"key":"754_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11523-017-0543-0","volume":"13","author":"MJ McKeage","year":"2018","unstructured":"McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L, Hughes BGM (2018) Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC. Target Oncol 13:89\u201398","journal-title":"Target Oncol"},{"key":"754_CR25","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-11-1027","volume":"11","author":"DW Jenkins","year":"2012","unstructured":"Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST (2012) MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol Cancer Ther 11:1650\u20131660","journal-title":"Mol Cancer Ther"},{"key":"754_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5966\/sctm.2012-0096","volume":"2","author":"CC Zhang","year":"2013","unstructured":"Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, Chen E, Lira ME, John-Baptiste A, Christensen JG (2013) Synergistic effect of the \u03b3-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl Med 2:233\u2013242","journal-title":"Stem Cells Transl Med"},{"key":"754_CR27","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1158\/1078-0432.CCR-11-3326","volume":"19","author":"AF Schott","year":"2013","unstructured":"Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC (2013) Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res 19:1512\u20131524","journal-title":"Clin Cancer Res"},{"key":"754_CR28","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1200\/JCO.2011.39.1540","volume":"30","author":"I Krop","year":"2012","unstructured":"Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P (2012) Phase I pharmacologic and pharmacodynamic study of the gamma secretase (notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 30:2307\u20132313","journal-title":"J Clin Oncol"},{"key":"754_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","volume":"21","author":"WA Messersmith","year":"2014","unstructured":"Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM (2014) A phase I, dose-finding study in patients with advanced solid malignancies of the oral \u03b3-secretase inhibitor PF-03084014. Clin Cancer Res 21:60\u201367","journal-title":"Clin Cancer Res"},{"key":"754_CR30","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1038\/bcj.2015.80","volume":"5","author":"C Papayannidis","year":"2015","unstructured":"Papayannidis C, DeAngelo DJ, Stock W, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, Ozeck M, Aster JC, Kuo F, Huang D, Lira PD, McLachlan KR, Kern KA, Garcia-Manero G, Martinelli G (2015) A phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer 5:e350","journal-title":"Blood Cancer"},{"key":"754_CR31","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1200\/JCO.2016.71.1994","volume":"35","author":"S Kummar","year":"2017","unstructured":"Kummar S, O'Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E, Choyke PL, Meehan R, Vilimas R, Horneffer Y, Juwara L, Lih A, Choudhary A, Mitchell SA, Helman LJ, Doroshow JH, Chen AP (2017) Clinical activity of the \u03b3-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). J Clin Oncol 35:1561\u20131569","journal-title":"J Clin Oncol"},{"key":"754_CR32","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1245\/s10434-017-6082-1","volume":"25","author":"VM Villalobos","year":"2018","unstructured":"Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W (2018) Long-term follow-up of desmoid fibromatosis treated with PF-03084014, an oral gamma secretase inhibitor. Ann Surg Oncol 25:768\u2013775","journal-title":"Ann Surg Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00754-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00754-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00754-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:40:49Z","timestamp":1678560049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00754-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00754-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"10 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"L. S. Rosen and A. W. Tolcher received research funding from Pfizer. R. Wesolowski served on an advisory board for Pfizer. R. Baffa, K-H. Liao, S. Y. Hua, B. L. Gibson, and S. Pirie-Shepherd were employees of Pfizer during the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Upon request, and subject to certain criteria, conditions and exceptions (see  for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24\u00a0months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}]}}